Balchem published its 2023 Sustainability Report, which captures the Company's commitment to managing our Environmental, Social and Governance (ESG) performance. This report demonstrates the Company's continuing promise to provide our employees, customers, shareholders and the communities within which we operate with information on Balchem's sustainability initiatives.
View Press Release
Related Resources
Balchem to Present First Quarter Financial Results on May 3, 2024.
Join Ted Harris, Chairman of the Board, President and CEO and Martin Bengtsson, CFO on Friday, May 3, 2024, at …
Balchem to Present First Quarter Financial Results on May 3, 2024
Join Ted Harris, Chairman of the Board, President and CEO and Martin Bengtsson, CFO on Friday, May 3, 2024, at …
Attachments
Original Link
Permalink
Disclaimer
Balchem Corporation published this content on
22 April 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
22 April 2024 11:04:08 UTC.
Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. The Company's segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. Through Specialty Products, it re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.
BALCHEM CORPORATION 
